IL130333A0 - Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists - Google Patents

Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists

Info

Publication number
IL130333A0
IL130333A0 IL13033397A IL13033397A IL130333A0 IL 130333 A0 IL130333 A0 IL 130333A0 IL 13033397 A IL13033397 A IL 13033397A IL 13033397 A IL13033397 A IL 13033397A IL 130333 A0 IL130333 A0 IL 130333A0
Authority
IL
Israel
Prior art keywords
agonists
prevention
treatment
receptor subtype
subtype selective
Prior art date
Application number
IL13033397A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL130333A0 publication Critical patent/IL130333A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
IL13033397A 1996-12-20 1997-11-27 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists IL130333A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3356996P 1996-12-20 1996-12-20
PCT/IB1997/001483 WO1998027976A1 (en) 1996-12-20 1997-11-27 Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists

Publications (1)

Publication Number Publication Date
IL130333A0 true IL130333A0 (en) 2000-06-01

Family

ID=21871174

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13033397A IL130333A0 (en) 1996-12-20 1997-11-27 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
IL130333A IL130333A (en) 1996-12-20 1999-06-07 Use of pharmaceutical preparations containing selective agonists of the EP2 receptor subtype in the preparation of drugs to prevent bone loss, increase bone mass and treat disorders associated with low bone mass

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL130333A IL130333A (en) 1996-12-20 1999-06-07 Use of pharmaceutical preparations containing selective agonists of the EP2 receptor subtype in the preparation of drugs to prevent bone loss, increase bone mass and treat disorders associated with low bone mass

Country Status (19)

Country Link
US (1) US6426359B1 (de)
EP (1) EP0951282B1 (de)
JP (2) JP2000507961A (de)
KR (1) KR100359557B1 (de)
AT (1) ATE390917T1 (de)
AU (1) AU4881697A (de)
CA (1) CA2275595C (de)
CY (1) CY2610B2 (de)
DE (1) DE69738613T2 (de)
DK (1) DK0951282T3 (de)
ES (1) ES2303341T3 (de)
HU (1) HUP0001836A3 (de)
IL (2) IL130333A0 (de)
MY (1) MY132818A (de)
NZ (1) NZ335770A (de)
PT (1) PT951282E (de)
TW (1) TW562677B (de)
WO (1) WO1998027976A1 (de)
ZA (1) ZA9711435B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
EP1000619A3 (de) * 1998-06-23 2002-07-24 Pfizer Products Inc. Verfahren zur Behandlung von Glaukoma
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU9756898A (en) * 1998-11-12 2000-06-05 Gemini Genomics Ab Human prostaglandin receptors and methods of use thereof
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
PL356662A1 (en) * 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
KR20040063981A (ko) * 2001-11-30 2004-07-15 화이자 프로덕츠 인크. Ｅｐ2 수용체 선택성 작용제를 포함하는 제약 조성물 및투여 방법
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
JP2006519250A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
EP1661580B1 (de) * 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Mittel zur behandlung von knorpelbedingten erkrankungen
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1723132A1 (de) 2004-02-12 2006-11-22 Asterand Uk Limited Agonisten des ep2-rezeptors
ATE465986T1 (de) 2005-01-14 2010-05-15 Allergan Inc Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
US8080567B2 (en) 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
US7323591B2 (en) * 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
WO2009065081A2 (en) * 2007-11-14 2009-05-22 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US8592413B2 (en) * 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033996A (en) * 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4112236A (en) * 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
AU615534B2 (en) 1988-04-19 1991-10-03 Teijin Limited 2-substituted-2-cyclopentenones
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater

Also Published As

Publication number Publication date
KR100359557B1 (ko) 2002-11-08
PT951282E (pt) 2008-06-09
HUP0001836A2 (hu) 2000-09-28
ES2303341T3 (es) 2008-08-01
EP0951282A1 (de) 1999-10-27
IL130333A (en) 2007-02-11
WO1998027976A1 (en) 1998-07-02
DE69738613T2 (de) 2009-04-30
AU4881697A (en) 1998-07-17
HUP0001836A3 (en) 2001-05-28
CY2610B2 (en) 2010-10-22
US6426359B1 (en) 2002-07-30
CA2275595C (en) 2003-08-05
ZA9711435B (en) 1999-06-21
DK0951282T3 (da) 2008-07-14
JP2000507961A (ja) 2000-06-27
ATE390917T1 (de) 2008-04-15
JP2006290895A (ja) 2006-10-26
KR20000057680A (ko) 2000-09-25
EP0951282B1 (de) 2008-04-02
CA2275595A1 (en) 1998-07-02
DE69738613D1 (de) 2008-05-15
NZ335770A (en) 2005-01-28
MY132818A (en) 2007-10-31
TW562677B (en) 2003-11-21

Similar Documents

Publication Publication Date Title
CY2610B2 (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists
BG102690A (en) Il-8 receptor antagonists
BG102726A (en) Combined therapy for osteoporosis
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
GB2333453A (en) Colostrinin and uses thereof
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
AU3508497A (en) Androgen receptor modulator compounds and methods
ATE234092T1 (de) 2-alkylpyrrolidine
HUT75555A (en) Lactobacillus strains of human origin, their compositions and uses thereof
WO2000006085A3 (en) Compounds and methods
AU1753699A (en) Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear
ID27820A (id) APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF
IL110943A0 (en) Compositions for the treatment of skin disorders
EP0909561A3 (de) Verwendung der Reboxetin zur Behandlung der Aufmerksamkeitsmangel/Hyperaktivität Störung
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
BR9510499A (pt) Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5
TR199900505T2 (de)
EP1632248B8 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
GB9805559D0 (en) A combination of therapeutic agents
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
IL139303A0 (en) Treatment of arthritis and other similar conditions
DK0956038T3 (da) Morfogen peptidinduceret regeneration af senseopfattelsesvæv

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed